Win a Grant to the C3 in Orlando, Florida

Participe por una beca para asistir al C3 en Orlando, FloridaFrom June 27th to June 30th, Orlando, Florida will hold the Complex Cardiovascular Catheter Therapeutics (C3 Conference), an event with a steadily growing number of attendees each year.

 

The Conference Organizing Committee grants, through SOLACI, five scholarships for professionals aiming to present their approved work or complex case.

 

Scholarships include the following:

  • Congress registration fee.
  • Three nights lodging for the aforementioned date.
  • Plane tickets through the Congress official travel agency (with a maximum limit of USD 1000).

 

 

How can you submit your work? 

Cases shall be submitted through the following form:

Enter 
(Spanish form)

 

Your presentation must fulfill the following requirements:

    • Submit a “.doc” or “.docx” file with the description of the case to be presented. The text must be up to 300 words long, in an 11 pt font.

 

    • Submit a supplementary “.ppt” or “.pptx” file with the case presentation. While videos (up to 5) will be admitted for use during the oral presentation, this initial file can only include up to 5 fixed images.

 

    • Case and description must be submitted in english.
  •  
    • Presenters can submit more than one case. In such a circumstance, they shall make different submissions, one for each presentation.
 

Submission deadline: March 30th, 2018.

 

C3 is a Congress designed for physicians who specialize in interventional cardiology, vascular surgery, and interventional radiology, as well as fellows, residents, and other healthcare professionals interested in atherosclerotic cardiovascular disease. C3 offers presentations and debates with expert global faculty, live and pre-recorded cases, industry-sponsored and supported symposia, exhibit booths and simulators, poster sessions, case presentations and hands-on workshops.

 

Learn more www.c3conference.net


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

 

More articles by this author

Unplanned Coronary Angiography After TAVR: Incidence, Predictors, and Outcomes

The importance of assessing coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) is well recognized due to the high prevalence of...

Uruguay Sessions 2025 | Young Interventional Cardiologists Contest

Call for Case Submission LI SOLACI Regional Sessions – 16° Southern Cone  It is with great pleasure that we hereby invite all young Latin American cardiologists...

TAVR Unload: TAVR in Moderate Aortic Stenosis and Ventricular Function Deterioration

Aortic Stenosis (AS) significantly contributes to valvulo-arterial impedance in patients with heart failure and reduced ejection fraction (HFrEF), making it a relevant therapeutic target...

TAVI and Hypertrophic Cardiomyopathy: An Increasingly Common Association

Stenosis is a common disease affecting 5% of the elderly population. It is associated with hospitalizations, poor quality of life, and mortality.  The association between...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Unplanned Coronary Angiography After TAVR: Incidence, Predictors, and Outcomes

The importance of assessing coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) is well recognized due to the high prevalence of...

Intravascular Lithotripsy in Calcified Coronary Lesions: Success Predictors

Coronary artery calcification (CAC) is increasingly common in patients undergoing percutaneous coronary intervention (PCI). Intravascular lithotripsy (IVL) has been established as an effective tool...

TAVR Unload: TAVR in Moderate Aortic Stenosis and Ventricular Function Deterioration

Aortic Stenosis (AS) significantly contributes to valvulo-arterial impedance in patients with heart failure and reduced ejection fraction (HFrEF), making it a relevant therapeutic target...